Galapagos NV (GLPGF)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Paulus A. Stoffels M.D., Ph.D. | CEO, Chairman, Interim Head of R&D | 1.34M | -- | 1962 |
| Mr. Thad Huston | Executive VP, CFO & COO | -- | -- | 1971 |
| Ms. Sofie Van Gijsel | Head of Investor Relations | -- | -- | -- |
| Ms. Valeria Cnossen | Executive VP & General Counsel | -- | -- | 1974 |
| Marieke Vermeersch | Head of Corporate Communication | -- | -- | -- |
| Ms. Annelies Missotten | Executive VP & Chief Human Resources Officer | -- | -- | 1973 |
| Ms. Ellen Van Der Aar | Head of Development | -- | -- | -- |
| Mr. Philippe Alen M.B.A., Ph.D., Pharm.D. | Senior VP & Head of Business Development | -- | -- | -- |
| Mr. Dirk De Naeyer | Head of Development Operations | -- | -- | -- |
| Ms. Alice Dietrich | Head of Medical Affairs | -- | -- | -- |
Galapagos NV
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 1,123
Description
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Corporate Governance
Recent Events
Recent Events Information Not Available
Upcoming Events
Upcoming Events Information Not Available